New drug combo shows promise against tough ovarian cancer
NCT ID NCT05296512
First seen Dec 18, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests two drugs, pembrolizumab and lenvatinib, in 30 people with recurrent clear cell ovarian cancer. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants must have had at least one prior treatment and measurable disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.